Trevi Therapeutics (TRVI) Set to Announce Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 12th. Analysts expect Trevi Therapeutics to post earnings of ($0.31) per share for the quarter.

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last released its quarterly earnings results on Thursday, March 17th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. During the same period in the prior year, the firm earned ($0.52) EPS. On average, analysts expect Trevi Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:TRVI traded down $0.18 during midday trading on Friday, hitting $2.32. 200 shares of the stock were exchanged, compared to its average volume of 1,796,110. The business’s 50-day moving average price is $2.23 and its 200 day moving average price is $1.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 2.98. The stock has a market capitalization of $89.76 million, a price-to-earnings ratio of -1.62 and a beta of 0.31. Trevi Therapeutics has a 12 month low of $0.46 and a 12 month high of $3.73.

In other Trevi Therapeutics news, major shareholder Paul Edward Walker purchased 3,580,526 shares of the company’s stock in a transaction on Monday, April 11th. The shares were purchased at an average cost of $1.90 per share, with a total value of $6,802,999.40. Following the completion of the purchase, the insider now owns 10,421,428 shares in the company, valued at $19,800,713.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 47.30% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC acquired a new position in Trevi Therapeutics in the third quarter valued at approximately $25,000. Millennium Management LLC acquired a new position in shares of Trevi Therapeutics during the fourth quarter worth approximately $95,000. Finally, Renaissance Technologies LLC raised its position in shares of Trevi Therapeutics by 415.1% during the fourth quarter. Renaissance Technologies LLC now owns 337,400 shares of the company’s stock worth $264,000 after purchasing an additional 271,900 shares during the period. 75.34% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the company. Zacks Investment Research raised Trevi Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Wednesday, March 23rd. Aegis assumed coverage on Trevi Therapeutics in a research note on Tuesday, March 29th. They issued a “buy” rating and a $10.00 price objective on the stock.

About Trevi Therapeutics (Get Rating)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Featured Articles